Cellectis gets access to a Japanese firm's iPS cell patents

10/18/2010 | Google

France's Cellectis has secured iPS Academia Japan's patents for induced pluripotent stem cells, according to a report by Kyodo News. The agreement allows Cellectis to use the cells to create treatments and to test the efficacy of drug candidates.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY